Analysis of 177 Cases of Adverse Drug Reactions Induced by Buflomedil

doi:10.19803/j.1672-8629.2020.01.11

Abstract

Abstract: Objective To analyze the characteristics of buflomedil adverse reactions (ADRs) and promote the clinical rational use of drugs. Methods A retrospective study was conducted to analyze 177 ADR reports collected in the 2008-2018 database of the adverse drug reaction monitoring system of Qinghai province. Results ADRs mostly occurred within 30 minutes, manifested as skin and accessory damage (51.04%), damage to the digestive system (15.77%), damage to the nervous system(10.37%), and damage to the circulatory system (8.71%). Conclusion The indications of the drug should be strictly controlled, and the process of drug administration should be closely observed to reduce the occurrence of ADRs.

Key words: buflomedil, safety analysis, adverse drug reactions

CLC Number:

R994.11

CHENG Xiaoping, GUAN Kang. Analysis of 177 Cases of Adverse Drug Reactions Induced by Buflomedil[J]. Chinese Journal of Pharmacovigilance, 2020, 17(1): 51-55.

References

[1] 李秀荣,杨辉.19例丁咯地尔注射液不良反应报告分析[J].药物流行病学杂志, 2009, 18(6):441-472.
[2] 王琼,王海芸,许巧巧,等.盐酸丁咯地尔的临床应用和不良反应[J].中国现代医生, 2012, 50(31):24-26.
[3] 傅宏义. 新编药物大全[M].4版.北京:中国医药科技出版社, 2015:181.
[4] 梁建兵. 盐酸丁咯地尔配合依达拉奉治疗脑梗塞64例临床疗效分析[J].实用妇科内分泌杂志, 2017, 36(4):178-181.
[5] Legras A,Piquemal R,Furet Y,etal.Buflomedil poisoning:five cases with cardiotoxicity[J].Intensive Care Med, 1996, 22(1):57-61.
[6] Neric C,Barbareschi M,Turrina S,et al.Suicide by buflomedil HCI:a case reprot[J].J Clin Forensic Med, 2004,11(1):15-16.
[7] 国家药品不良反应监测中心,国家药品监督管理局药品评价中心.SFDA修改丁咯地尔说明书[G].药物警戒快讯,2007, 9:7
[8] 梁秀琳,毛庆,侍海存,等.丁咯地尔致不良反应分析[J].中国医药指南, 2010, 15(8):63-64.
[9] Martínez-Sierra R,Lara B,Torres A.Bu flomedil intoxication:the lit-tle-known risk[J].J Toxicol Clin Toxicol, 1992, 30(2):305.
[10] 王海延. 超声雾化丁咯地尔注射液治疗干燥性咽炎疗效观察[J].实用医技杂志, 2002, 9(12):938.
[11] 任经天. 浅谈我国药品上市后临床研究的监管[J].中国药物警戒, 2007, 4(2):68-73.
[12] 蒋彦章. WHO全球药物不良反应信息(32)[J].药物流行病学杂志, 2008, 17(2):132.
[13] Fick D M, Waller J L, Madean J R, et al.Cangialose potentially in appropriate medication use in a medicare managed care population:association with higher costs and utilization[J].J Managed Care Pharm, 2017, 7(5):407-413.
[14] 桑媛,吴世福,路长飞.检查视角下生产企业药品不良反应报告与监测的问题及思考[J].中国药物警戒, 2019, 16(4):215-218.

[1]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[2]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[3]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[4]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[5]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[6]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[7]	ZANG Tianying, LIU Bingyang, TANG Xiaojun. Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.
[8]	CHANG Yongzhuo, LI Ji, ZHANG Xiaoyan, ZHOU Chaofan. One case of abnormal uterine bleeding caused by Baofukang suppository [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 935-938.
[9]	WANG Shuwei, YIN Jinjun, WANG Bing, SONG Caiping, YANG Fujun. Axitinib tablets combined with toripalimab injection in the treatment of renal cancer-induced central retinal artery occlusion: a case report [J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 825-828.
[10]	ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia. Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
[11]	LI Tan, ZHANG Yang, ZHANG Wangde, WANG Yun. Efficacy and safety of different analgesia drugs in the treatment of lower extremity ischemic pain [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 680-683.
[12]	CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
[13]	. Annual report of national adverse drug reaction monitoring (2022) [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
[14]	CHEN Cheng, DENG Li, LIU Songqing, DU Qian, XI Xin. Analysis of reports of allergic shock in Chongqing between 2015 and 2020 [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 460-464.
[15]	OUYANG Ying, ZHONG Changxin, XIA Chunhua, NIE Jungang, ZHOU Ying. One case of breast hyperplasia caused by digoxin tablets [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 346-347.